EA
VRDN icon

Emerald Advisers’s Viridian Therapeutics VRDN Stock Holding History

Emerald Advisers’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.87M Buy
+537,328
New +$8.66M 0.23% 110

Other funds holding VRDN

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM

Emerald Advisers's VRDN Position: Q2 2026 in Review

Emerald Advisers opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 537,328 shares worth $9.87M. The stake represents 0.23% of the portfolio and ranks #110 among its holdings.

44 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Emerald Advisers held 537,328 shares of Viridian Therapeutics worth $9.87M as of Q2 2026.
  • Viridian Therapeutics was a new Emerald Advisers position in Q2 2026.
  • Viridian Therapeutics made up 0.23% of Emerald Advisers's portfolio in Q2 2026, its #110 holding.
  • 44 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.